Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of nanofiltered plasma-derived factor IX in previously treated hemophilia B patients
2005-006186-14Phase 2Completed
- Sponsor
- Kedrion Biopharma
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of coagulation factor IX in hemophilia B (HB), sponsored by Kedrion Biopharma. Primary endpoints: Pharmacokinetics of nanofiltered factor IX, Hemostatic efficacy in acute bleeding events and 3 more. Started Nov 2007; status: completed.
02
Drugs
coagulation factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2005-006186-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006186-14.